Policy / Pricing Most patients “won’t see benefit” with Alzheimer’s drugs PharmaphorumA review of clinical data on amyloid-targeting Alzheimer's therapies has found absent or trivial efficacy, but is facing pushback from some experts.Policy / PricingNeuroscienceRead full story pharminent April 16, 2026 (Last updated: April 16, 2026) Pharmaphorum A review of clinical data on amyloid-targeting Alzheimer’s therapies has found absent or trivial efficacy, but is facing pushback from some experts. Policy / PricingNeuroscienceRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Terremoto wins $108m in Series C to drive cancer and rare disease programmesNext: Beeline raises $300m for BMS drugs, and other biofinancings Related Stories Policy / Pricing US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028 pharminent July 22, 2026 Policy / Pricing UK commits to pharma IP protection in Swiss trade deal pharminent July 16, 2026 Policy / Pricing Germany approves healthcare costs overhaul despite significant pharma opposition pharminent July 13, 2026
